Sallinen J, Haapalinna A, Viitamaa T, Kobilka B K, Scheinin M
Department of Pharmacology and Clinical Pharmacology, University of Turku, FIN-20520 Turku, Finland.
J Neurosci. 1998 Apr 15;18(8):3035-42. doi: 10.1523/JNEUROSCI.18-08-03035.1998.
Studies on animal models of stress, anxiety, aggression, and sensorimotor gating have linked specific monoamine neurotransmitter abnormalities to the cognitive and behavioral disturbances associated with many affective neuropsychiatric disorders. Although alpha2-adrenoceptors (alpha2-ARs) have been suggested to have a modulatory role in these disorders, the specific roles of each alpha2-AR subtype (alpha2A, alpha2B, and alpha2C) are largely unknown. The restricted availability of relevant animal models and the lack of subtype-selective alpha2-AR drugs have precluded detailed studies in this area. Therefore, transgenic mice were used to study the possible role of the alpha2C-AR subtype in two well established behavioral paradigms: prepulse inhibition (PPI) of the startle reflex and isolation-induced aggression. The alpha2C-AR-altered mice appear grossly normal, but subtle changes have been observed in their brain dopamine (DA) and serotonin (5-HT) metabolism. In this study, the mice with targeted inactivation of the gene encoding alpha2C-ARs (alpha2C-KO) had enhanced startle responses, diminished PPI, and shortened attack latency in the isolation-aggression test, whereas tissue-specific overexpression of alpha2C-ARs (alpha2C-OE) was associated with opposite effects. Correlation analyses suggested that both the magnitude of the startle response and its relative PPI (PPI%) were modulated by the mutations. In addition, the differences in PPI, observed between drug-naive alpha2C-OE mice and their wild-type controls, were abolished by treatment with a subtype nonselective alpha2-agonist and antagonist. Thus, drugs acting via alpha2C-ARs might have therapeutic value in disorders associated with enhanced startle responses and sensorimotor gating deficits, such as schizophrenia, attention deficit disorder, post-traumatic stress disorder, and drug withdrawal.
对压力、焦虑、攻击行为和感觉运动门控的动物模型研究表明,特定的单胺神经递质异常与许多情感性神经精神障碍相关的认知和行为障碍有关。尽管α2 - 肾上腺素能受体(α2 - ARs)被认为在这些疾病中起调节作用,但每种α2 - AR亚型(α2A、α2B和α2C)的具体作用在很大程度上尚不清楚。相关动物模型的可用性有限以及缺乏亚型选择性α2 - AR药物阻碍了该领域的详细研究。因此,利用转基因小鼠在两种成熟的行为范式中研究α2C - AR亚型的可能作用:惊吓反射的前脉冲抑制(PPI)和隔离诱导的攻击行为。α2C - AR改变的小鼠外观大体正常,但在其脑多巴胺(DA)和5 - 羟色胺(5 - HT)代谢中观察到了细微变化。在本研究中,编码α2C - ARs的基因靶向失活的小鼠(α2C - KO)在隔离攻击试验中惊吓反应增强、PPI减弱且攻击潜伏期缩短,而α2C - ARs的组织特异性过表达(α2C - OE)则产生相反的效果。相关性分析表明,惊吓反应的幅度及其相对PPI(PPI%)均受突变调节。此外,未经药物处理的α2C - OE小鼠与其野生型对照之间观察到的PPI差异,在用亚型非选择性α2 - 激动剂和拮抗剂处理后消失。因此,通过α2C - ARs起作用的药物可能对与惊吓反应增强和感觉运动门控缺陷相关的疾病具有治疗价值,如精神分裂症、注意力缺陷障碍、创伤后应激障碍和药物戒断。